Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome
- PMID: 2415251
Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome
Abstract
Multivariate analysis was used to identify which of a large number of pretreatment immunological parameters correlated with therapeutic response, subsequent development of opportunistic infection, and survival from the time of diagnosis in a group of 70 patients with Kaposi's sarcoma and acquired immunodeficiency syndrome treated with recombinant leukocyte A interferon. In a logistic regression model, delayed type hypersensitivity response to one or more recall antigens and high proliferative response to Escherichia coli were significant predictors for response to recombinant leukocyte A interferon (for the model, P = 0.01). For prediction of the development of opportunistic infection, the model selected low proliferative responses to phytohemagglutinin and E. coli (P less than 0.001). Favorable factors predicting survival in the Cox regression model were the absence of endogenous serum interferon activity and a high proliferative response to E. coli (P less than 0.001). The estimated median survival for the group with endogenous serum interferon activity and low E. coli response was 12 months; the median has not yet been reached for the group with no serum interferon and a high E. coli response. We conclude that immunological parameters may be useful in predicting prognosis in patients with Kaposi's sarcoma and acquired immunodeficiency syndrome.
Similar articles
-
Combination chemotherapy and alpha-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome.CMAJ. 1988 Oct 1;139(7):635-9. CMAJ. 1988. PMID: 2458177 Free PMC article. Clinical Trial.
-
Kaposi's sarcoma and AIDS: a variable spectrum.Clin Invest Med. 1989 Dec;12(6):367-73. Clin Invest Med. 1989. PMID: 2612089
-
Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma.N Engl J Med. 1983 May 5;308(18):1071-6. doi: 10.1056/NEJM198305053081806. N Engl J Med. 1983. PMID: 6835320 No abstract available.
-
Biotherapy with interferon in AIDS-related Kaposi's sarcoma.Oncol Nurs Forum. 1987 Nov-Dec;14(6 Suppl):27-31. Oncol Nurs Forum. 1987. PMID: 3320983 Review. No abstract available.
-
Therapeutic approaches to patients with AIDS.Cancer Res. 1985 Sep;45(9 Suppl):4674s-4676s. Cancer Res. 1985. PMID: 2990706 Review.
Cited by
-
Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments.Virus Genes. 2009 Apr;38(2):195-203. doi: 10.1007/s11262-008-0325-y. Epub 2009 Jan 13. Virus Genes. 2009. PMID: 19139983 Review.
-
The use of interferon-alpha in virus infections.Drugs. 1991 Nov;42(5):749-65. doi: 10.2165/00003495-199142050-00003. Drugs. 1991. PMID: 1723372 Free PMC article. Review.
-
[Virus-specific antibody profile in various stages of HIV-1 infection. Western blot analysis of 170 patients].Klin Wochenschr. 1988 Jun 1;66(11):488-93. doi: 10.1007/BF01876170. Klin Wochenschr. 1988. PMID: 3165484 German.
-
The role of interferons in the treatment of malignant neoplasms.Yale J Biol Med. 1989 May-Jun;62(3):271-90. Yale J Biol Med. 1989. PMID: 2479178 Free PMC article. Review.
-
Combination chemotherapy and alpha-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome.CMAJ. 1988 Oct 1;139(7):635-9. CMAJ. 1988. PMID: 2458177 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical